CN111471041B - Synthetic method of oxazolidinone antibacterial drug intermediate - Google Patents
Synthetic method of oxazolidinone antibacterial drug intermediate Download PDFInfo
- Publication number
- CN111471041B CN111471041B CN201910065066.1A CN201910065066A CN111471041B CN 111471041 B CN111471041 B CN 111471041B CN 201910065066 A CN201910065066 A CN 201910065066A CN 111471041 B CN111471041 B CN 111471041B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- synthesis
- reagent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a synthetic method of an oxazolidinone antibacterial drug intermediate, which comprises the following steps: (1) acetate derivatives IV-1 and 2, 5-disubstituted pyridine IV-2 react in an organic solvent under the action of a metal reagent to obtain a compound IV-3; (2) carrying out reduction reaction on the compound IV-3 in an organic solvent in the presence of a reducing agent to obtain a compound IV-4; (3) reacting the compound IV-4 with methylamine solution to obtain a compound IV-5; (4) carrying out salt forming reaction on the compound IV-5 and chiral acid at the temperature of 20-100 ℃, recrystallizing the obtained salt, and dissociating under the action of alkali to obtain a compound III-4; (5) and carrying out cyclization reaction on the compound III-4 in the presence of a cyclization reagent to obtain the oxazolidinone antibacterial drug intermediate II-8. The method overcomes the defects of the prior art that explosive azide and expensive metal catalysts are adopted, has mild and safe reaction conditions, easily purchased reagents, low cost, shortened reaction steps, avoids column chromatography and is beneficial to industrial production.
Description
Technical Field
The invention belongs to the field of synthesis of pharmaceutical and chemical intermediates, and mainly relates to a synthesis method of an oxazolidinone antibacterial drug intermediate.
Background
The problem of bacterial resistance worldwide is becoming more serious due to abuse of antibiotics, and presents a great challenge to clinical anti-infection treatment, so that the development of antibacterial drugs with brand new action mechanisms is urgent. The oxazolidinone antibacterial drug has a brand new action mechanism different from the existing antibacterial drugs, has good antibacterial activity on various common clinical drug-resistant bacteria, and brings eosin for solving the problem of drug resistance clinically.
Patent reports (ZL201210576376.8) disclose a new tricyclic oxazolidinone antibacterial drug, and representative compounds thereof are shown in formula I:
wherein M is H or pharmaceutically acceptable salts such as alkali metal, alkaline earth metal, basic amino acid and the like.
The in vivo MRSA (methicillin resistant Staphylococcus aureus) activity of the compound (M ═ Na) of the formula I is 2 times that of linezolid, more importantly, the compound also has high antibacterial activity to linezolid resistant bacteria, and thus a powerful weapon is provided for clinically solving the problem of linezolid resistance. The compound of formula I (M ═ Na) has good water solubility, can be taken orally or injected for administration, and has excellent pharmacokinetic property, half-life and AUC, and in-vitro and in-vivo antibacterial activity superior to linezolid in rats and dogs. The literature (Journal of medicinal Chemistry,2013,56,2642-2650) reports the synthesis of novel oxazolidinone antibacterial drugs in formula I as follows:
a key chiral intermediate II-8 (hereinafter referred to as an oxazolidinone antibacterial drug intermediate) is involved in the route, and the synthesis efficiency of the chiral intermediate II-8 has important influence on the whole route. The literature reports that the above synthetic route for intermediate II-8 has several disadvantages: (1) the reaction involves expensive metal catalyst, the production cost is too high; (2) the reaction involves explosive azide and needs to be carried out at high temperature, so that potential safety problems exist; (3) column chromatography is generally adopted in the post-treatment of the multi-step reaction, and the method is not suitable for industrial mass production.
Another synthesis method of the intermediate II-8 is reported in the patent (CN201610368999.4), and the reaction route is as follows:
however, the route still needs expensive metal catalysts, the production cost is too high, the chiral reduction reaction conditions are harsh, and the method is not suitable for industrial mass production.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides an improved synthesis method of an oxazolidinone antibacterial drug intermediate, which avoids the use of explosive azide and expensive metal catalysts, has higher safety and lower synthesis cost, and is suitable for industrial mass production.
A synthetic method of an oxazolidinone antibacterial drug intermediate comprises the following steps:
(1) acetate derivatives IV-1 and 2, 5-disubstituted pyridine IV-2 react in an organic solvent under the action of a metal reagent to obtain a compound IV-3;
(2) carrying out reduction reaction on the compound IV-3 in an organic solvent in the presence of a reducing agent to obtain a compound IV-4;
(3) reacting the compound IV-4 with methylamine solution to obtain a compound IV-5;
(4) carrying out salt forming reaction on the compound IV-5 and chiral acid (HA) at the temperature of 20-100 ℃, recrystallizing the obtained salt, and dissociating under the action of alkali to obtain a compound III-4;
(5) carrying out cyclization reaction on the compound III-4 in the presence of a cyclization reagent to obtain an oxazolidinone antibacterial drug intermediate II-8;
in the formula R 1 Selected from chlorine, bromine, iodine, -OSO 2 R 4 Wherein R is 4 Selected from unsubstituted or substituted C 1 -C 6 Straight or branched alkyl, unsubstituted or substituted C 3 -C 6 Cycloalkyl, unsubstituted or substituted C 6 -C 14 Aryl or unsubstituted or substituted 5-14 membered heteroaryl, wherein said substitution is by one or more groups selected from halogen, nitro, C 1 -C 6 Alkyl is substituted by a substituent; the heteroaryl group comprises 1-3 heteroatoms selected from N, O, S; r 2 Is selected from C 1 -C 6 Straight or branched alkyl of (2), C 3 -C 6 Cycloalkyl, benzyl (i.e. -CH) 2 -phenyl); r is 3 Selected from fluorine, chlorine, bromine, iodine.
In the step (1), preferably, the acetate derivative IV-1 is selected from ethyl chloroacetate, methyl chloroacetate, ethyl bromoacetate, propyl chloroacetate, butyl chloroacetate, amyl chloroacetate, benzyl chloroacetate, ethyl bromoacetate, and methyl bromoacetate; more preferably, the acetate derivative IV-1 is ethyl chloroacetate. Preferably, the 2, 5-disubstituted pyridine IV-2 is 2, 5-dibromopyridine, 5-bromo-2-iodopyridine or 5-bromo-2-chloropyridine; more preferably, the 2, 5-disubstituted pyridine IV-2 is 2, 5-dibromopyridine. Preferably, the metal reagent is an organic lithium reagent or a Grignard reagent; more preferably, the metal reagent is n-butyllithium. The organic solvent is toluene or dichloromethane; more preferably, the organic solvent is toluene; preferably, the reaction temperature is from 0 to-78 ℃; preferably, the reaction time is from 1 to 12 hours.
In the step (2), preferably, the reducing agent is sodium borohydride, lithium borohydride, borane, aluminum isopropoxide or lithium aluminum hydride; more preferably, the reducing agent is sodium borohydride. The organic solvent is one or a mixture of more than two of methanol, ethanol, isopropanol and tetrahydrofuran; preferably, the reaction temperature is-20 to 30 ℃; preferably, the reaction time is from 0.5 to 8 hours.
In the step (3), preferably, the methylamine solution is methylamine alcohol solution or methylamine water solution; more preferably, the methylamine solution is an aqueous methylamine solution. Preferably, the reaction temperature is from 0 to 80 ℃; preferably, the reaction time is from 0.5 to 12 hours.
In the step (4), preferably, the chiral acid is selected from the group consisting of L-tartaric acid, D-tartaric acid, L- (-) -dibenzoyltartaric acid, D- (+) -di-p-methylbenzoyltartaric acid, (-) -di-p-toluoyl-L-tartaric acid, (-) -di-pivaloyl-L-tartaric acid, D- (-) -quinic acid, D-camphoric acid, D- (+) -malic acid, (S) - (+) -O-acetyl-L-mandelic acid, (-) -O-acetyl-D-mandelic acid, D (+) -10-camphorsulfonic acid, L- (-) -L-toluoyltartaric acid, L-tartaric acid, L- (-) -tartaric acid, L-toluoyltartaric acid, L-tartaric acid, L- (-) -toluoyltartaric acid, L-tartaric acid, L- (-) -tartaric acid, L-tartaric acid, and the salt, and the like, D-aspartic acid, L-aspartic acid, D- (-) -mandelic acid or L- (+) -mandelic acid; more preferably, the chiral acid is D- (-) -mandelic acid; the solvent used for recrystallization is one or more selected from acetonitrile, tetrahydrofuran, methanol, isopropanol, ethanol and water. The alkali is selected from sodium hydroxide, potassium hydroxide or lithium hydroxide; preferably, the reaction temperature is 20 to 100 ℃; preferably, the reaction time is from 1 to 12 hours.
In the step (5), preferably, the cyclizing reagent is N, -carbonyldiimidazole, phosgene or triphosgene; more preferably, the cyclizing reagent is N, N, -carbonyldiimidazole. Preferably, the reaction temperature is from 0 to 80 ℃; preferably, the reaction time is from 1 to 12 hours.
Compared with the prior art, the invention has the following advantages: the invention provides a method for splitting an oxazolidinone antibacterial drug intermediate, which overcomes the defects that explosive azide compounds and expensive metal catalysts are adopted in the prior art, has mild and safe reaction conditions, easily purchased reduction reagents and low cost, shortens reaction steps, avoids column chromatography, is more beneficial to industrial production and has good application prospect.
Detailed description of the invention
Specific embodiments of the present invention are illustrated by reference to the following examples, which are intended to illustrate the invention and not to limit it in any way.
EXAMPLE 1 Synthesis of Compound II-3
Dissolving 2, 5-dibromopyridine II-2(25.00g,0.12mol) in dry toluene (1000mL), cooling to-78 ℃, dropwise adding n-butyllithium (56.00mL,0.14mol,2.5M n-hexane solution), stirring for 2 hours after the addition is finished, dropwise adding ethyl chloroacetate V-1(13.73mL,0.13mol, dissolving in 20mL of toluene), stirring for 2 hours after the dropwise addition is finished, adding 10% ammonium chloride solution for quenching reaction, raising the temperature to room temperature, adding water for dilution, separating a toluene layer, extracting an aqueous phase once with ethyl acetate, combining organic phases, washing with water and saturated saline water in sequence, drying with anhydrous sodium sulfate, filtering, concentrating, and recrystallizing with ethanol-water (volume ratio 10/1) to obtain 14.53g of an off-white solid with the yield of 52%. 1 H NMR(600MHz,CDCl 3 )δ8.73(d,J＝2.1Hz,1H),8.02(dd,J＝8.4, 2.2Hz,1H),7.99(dd,J＝8.3,0.9Hz,1H),5.06(s,2H).
EXAMPLE 2 Synthesis of Compound V-2
Dissolving II-3(25g,107.33mmol) in methanol (250ml), cooling to 0 ℃, adding sodium borohydride (4.87g,128.80mmol) in batches, removing the ice water bath, reacting at room temperature for 2h, reacting completely, slowly adding saturated ammonium chloride solution under cooling to quench the reaction, evaporating the methanol, extracting the water phase twice with ethyl acetate, washing the organic phase with water and saturated salt solution in turn, drying with anhydrous sodium sulfate, filtering, concentrating to obtain a viscous crude product V-2, and directly putting the viscous crude product V-2 into the next step for reaction without purification. 1 H NMR(400MHz,CDCl 3 )δ8.65(s,1H), 7.88(d,J＝8.6Hz,1H),7.38(d,J＝8.3Hz,1H),4.96(t,J＝5.4Hz,1H),3.90–3.85 (m,1H),3.85–3.77(m,1H).
EXAMPLE 3 Synthesis of Compound IV-5
Dissolving the crude product in the previous step by using ethanol (260mL), adding methylamine water solution (260mL), reacting for 3h at 40 ℃, concentrating, adjusting the pH to 6 by using 1N HCl solution, extracting for three times by using dichloromethane, discarding an organic phase, adjusting the pH of an aqueous phase to 12 by using 1N sodium hydroxide solution, extracting by using dichloromethane until no product exists, combining the organic phases, washing by using water and saturated saline in sequence, drying by using anhydrous sodium sulfate, filtering, and concentrating to obtain 19.7g of white solid, wherein the yield of the two steps is 80%. 1 H NMR(400MHz,CDCl 3 )δ8.60(d,J＝2.3Hz,1H), 7.82(dd,J＝8.4,2.4Hz,1H),7.37(d,J＝8.4Hz,1H),4.77(dd,J＝7.9,3.8Hz,1H), 2.99(dd,J＝12.2,3.8Hz,1H),2.77(dd,J＝12.1,7.9Hz,1H),2.46(s,3H).
EXAMPLE 4 Synthesis of Compound III-4
Dissolving IV-5(8g,34.78mmol) in acetonitrile (100ml), heating to 70 deg.C, adding D-mandelic acid (2.64g,17.39mmol), reacting at 70 deg.C for 3h, and concentrating to obtain white solid; adding the obtained white solid into acetonitrile (50ml) and water (2ml), heating to 70 ℃, preserving heat for 3h, then slowly cooling to 4 ℃, and separating out 5.7g of white solid; 5.7g of the solid was added to acetonitrile (50ml) and water (2ml), and the above operation was repeated to obtain 3.8g of a white solid. 3.8g of white solid was dissolved in water, the pH was adjusted to 12 with 1N sodium hydroxide solution, extraction was carried out twice with methylene chloride, and concentration was carried out to obtain 2.45g of white solid, yield 31%, ee value 97%. 1 H NMR(400MHz,CDCl 3 )δ8.62(dd,J＝2.3,0.7Hz,1H),7.85(dd,J＝8.3,2.3Hz, 1H),7.39(d,J＝8.4Hz,1H),4.81(dd,J＝7.9,3.9Hz,1H),3.02(dd,J＝12.1,3.9 Hz,1H),2.80(dd,J＝12.1,7.9Hz,1H),2.49(s,3H).
EXAMPLE 5 Synthesis of Compound II-8
III-4(2g,8.7mmol) was dissolved in THF (15ml), 4-dimethylaminopyridine (225mg, 1.74mmol) and CDI (2.24g,13.0mmol) were added and reacted at room temperature for 5h, ethyl acetate was added and KHSO was added successively 4 The solution was washed with water and saturated brine, dried over anhydrous sodium sulfate, concentrated and recrystallized from ethyl acetate-n-heptane (volume ratio 1/10) to give 1.6g of a white solid, yield 73%, ee value: 99.5 percent. 1 H NMR(600 MHz,Chloroform-d)δ8.64(d,J＝2.2Hz,1H),7.89(dd,J＝8.4,2.3Hz,1H),7.45 (d,J＝8.3Hz,1H),5.51(dd,J＝9.1,6.0Hz,1H),4.00(t,J＝9.0Hz,1H),3.71(dd,J ＝8.9,6.0Hz,1H),2.91(s,3H).
EXAMPLE 6 Synthesis of Compound V-4
Dissolving 2, 5-dibromopyridine II-2(25.00g,0.12mol) in dry toluene (1000ml), cooling to-78 ℃, dropwise adding n-butyllithium (56.00ml,0.14mol,2.5M n-hexane solution), stirring for 2 hours after the addition is finished, dropwise adding ethyl methylsulfonyloxyacetate V-3(23.66g,0.13mol, dissolving in 20ml toluene), stirring for 2 hours after the dropwise addition is finished, adding 10% ammonium chloride solution for quenching reaction, raising to room temperature, adding water for dilution, separating a toluene layer, extracting an aqueous phase once with ethyl acetate, combining organic phases, washing with water and saturated common salt solution in sequence, drying with anhydrous sodium sulfate, filtering, concentrating, and recrystallizing with ethanol-water (volume ratio 10/1) to obtain an off-white solid of 16.87g and yield of 48%. 1 H NMR(600MHz,CDCl 3 )δ8.71(d,J＝2.1Hz,1H),8.03 (dd,J＝8.4,2.2Hz,1H),7.96(dd,J＝8.3,0.9Hz,1H),5.92(s,2H),3.36(s,3H).
EXAMPLE 7 Synthesis of Compound V-5
Dissolving V-4(15g,51.2mmol) in methanol (250ml), cooling to 0 ℃, adding sodium borohydride (2.9g,76.8mmol) in batches, removing the ice water bath, reacting at room temperature for 2h, reacting completely, slowly adding saturated ammonium chloride solution under cooling to quench the reaction, evaporating the methanol, extracting the water phase twice with ethyl acetate, washing the organic phase with water and saturated salt solution in turn, drying with anhydrous sodium sulfate, filtering, concentrating to obtain a viscous crude product V-5, and directly feeding the crude product V-5 to the next step for reaction without purification. 1 H NMR(400MHz,CDCl 3 )δ8.63(s,1H), 7.86(d,J＝8.6Hz,1H),7.35(d,J＝8.3Hz,1H),4.98(t,J＝5.4Hz,1H),3.92–3.88 (m,1H),3.87–3.80(m,1H),3.35(s,3H).
EXAMPLE 8 Synthesis of Compound IV-5
The crude product obtained in example 7 was dissolved in ethanol (150mL), aqueous methylamine solution (150mL) was added, reaction was carried out at 40 ℃ for 3h, concentration was carried out, pH was adjusted to 6 with 1N HCl solution, extraction was carried out three times with dichloromethane, the organic phase was discarded, then the aqueous phase was adjusted to pH 12 with 1N sodium hydroxide solution, extraction was carried out with dichloromethane until no product was obtained, the organic phases were combined, washed successively with water and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give 9.2g of a white solid with a yield of 78% in two steps. 1 H NMR(400MHz,CDCl 3 )δ8.60(d,J＝2.3Hz, 1H),7.82(dd,J＝8.4,2.4Hz,1H),7.37(d,J＝8.4Hz,1H),4.77(dd,J＝7.9,3.8Hz, 1H),2.99(dd,J＝12.2,3.8Hz,1H),2.77(dd,J＝12.1,7.9Hz,1H),2.46(s,3H)。
Claims (14)
1. A synthetic method of an oxazolidinone antibacterial drug intermediate is characterized by comprising the following steps:
(1) reacting an acetate derivative IV-1 and 2, 5-disubstituted pyridine IV-2 in an organic solvent under the action of a metal reagent to obtain a compound IV-3;
(2) carrying out reduction reaction on the compound IV-3 in an organic solvent in the presence of a reducing agent to obtain a compound IV-4;
(3) reacting the compound IV-4 with methylamine solution to obtain a compound IV-5;
(4) carrying out salt forming reaction on the compound IV-5 and chiral acid at the temperature of 20-100 ℃, recrystallizing the obtained salt, and dissociating under the action of alkali to obtain a compound III-4;
(5) carrying out cyclization reaction on the compound III-4 in the presence of a cyclization reagent to obtain an oxazolidinone antibacterial drug intermediate II-8;
in the formula R 1 Selected from chlorine, bromine, iodine, -OSO 2 R 4 Wherein R is 4 Selected from unsubstituted or substituted C 1 -C 6 Straight or branched alkyl, unsubstituted or substituted C 3 -C 6 Cycloalkyl, unsubstituted or substituted C 6 -C 14 Aryl or unsubstituted or substituted 5-14 membered heteroaryl, wherein said substitution is by one or more groups selected from halogen, nitro, C 1 -C 6 Alkyl is substituted by a substituent; the heteroaryl group comprises 1-3 heteroatoms selected from N, O, S; r 2 Is selected from C 1 -C 6 Straight or branched alkyl of (2), C 3 -C 6 Cycloalkyl, benzyl; r 3 Selected from fluorine, chlorine, bromine, iodine.
2. The method of synthesis of claim 1, wherein:
in the step (1), the acetate derivative IV-1 is selected from ethyl chloroacetate, methyl chloroacetate, ethyl bromoacetate, propyl chloroacetate, butyl chloroacetate, pentyl chloroacetate, benzyl chloroacetate and methyl bromoacetate;
in the step (1), the 2, 5-disubstituted pyridine IV-2 is 2, 5-dibromopyridine, 5-bromo-2-iodopyridine or 5-bromo-2-chloropyridine;
in the step (1), the metal reagent is an organic lithium reagent or a Grignard reagent;
in the step (1), the organic solvent is toluene or dichloromethane.
3. The method of synthesis of claim 2, wherein: in the step (1), the acetate derivative IV-1 is ethyl chloroacetate.
4. A method of synthesis as claimed in claim 2 or 3, wherein: in the step (1), the 2, 5-disubstituted pyridine IV-2 is 2, 5-dibromopyridine.
5. A method of synthesis as claimed in claim 2 or 3, wherein: in the step (1), the metal reagent is n-butyl lithium.
6. A method of synthesis according to claim 2 or 3, characterised in that: in the step (1), the organic solvent is toluene.
7. The method of synthesis of claim 1, wherein:
in the step (2), the reducing agent is sodium borohydride, lithium borohydride, borane, aluminum isopropoxide or lithium aluminum hydride; the organic solvent is one or a mixture of more than two of methanol, ethanol, isopropanol and tetrahydrofuran.
8. The method of synthesis of claim 7, wherein: in the step (2), the reducing agent is sodium borohydride.
9. The method of synthesis of claim 1, wherein: in the step (3), the methylamine solution is methylamine alcohol solution or methylamine water solution.
10. The method of synthesis of claim 1, wherein: in the step (3), the methylamine solution is a methylamine aqueous solution.
11. The method of synthesis of claim 1, wherein:
in the step (4), the chiral acid is selected from the group consisting of L-tartaric acid, D-tartaric acid, L- (-) -dibenzoyltartaric acid, D- (+) -di-p-methylbenzoyltartaric acid, (-) -di-p-toluoyl-L-tartaric acid, (-) -di-pivaloyl-L-tartaric acid, D- (-) -quinic acid, D-camphoric acid, D- (+) -malic acid, (S) - (+) -O-acetyl-L-mandelic acid, (-) -O-acetyl-D-mandelic acid, D (+) -10-camphorsulfonic acid, L- (-) -camphorsulfonic acid, L- (-) -L-toluic acid, L- (-) -toluic acid, L- (-) -toluic acid, L-toluic acid, L- (-) -toluic acid, L-tartaric acid, L- (-) -toluic acid, L-tartaric acid, and L-beta-, D-aspartic acid, L-aspartic acid, D- (-) -mandelic acid or L- (+) -mandelic acid;
in the step (4), the solvent used for recrystallization is selected from one or more of acetonitrile, tetrahydrofuran, methanol, isopropanol, ethanol and water;
in the step (4), the alkali is selected from sodium hydroxide, potassium hydroxide or lithium hydroxide.
12. The method of synthesis of claim 11, wherein: the chiral acid is D- (-) -mandelic acid.
13. The method of synthesis of claim 1, wherein: in the step (5), the cyclizing reagent is N, N' -carbonyldiimidazole, phosgene or triphosgene.
14. The method of synthesis of claim 13, wherein: in the step (5), the cyclizing reagent is N, N' -carbonyldiimidazole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910065066.1A CN111471041B (en) | 2019-01-23 | 2019-01-23 | Synthetic method of oxazolidinone antibacterial drug intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910065066.1A CN111471041B (en) | 2019-01-23 | 2019-01-23 | Synthetic method of oxazolidinone antibacterial drug intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111471041A CN111471041A (en) | 2020-07-31 |
| CN111471041B true CN111471041B (en) | 2022-09-20 |
Family
ID=71743344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910065066.1A Active CN111471041B (en) | 2019-01-23 | 2019-01-23 | Synthetic method of oxazolidinone antibacterial drug intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111471041B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113620897A (en) * | 2021-09-06 | 2021-11-09 | 南京杰运医药科技有限公司 | Preparation method of oxazolidinone compound |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101798302A (en) * | 2009-02-06 | 2010-08-11 | 盟科医药技术(上海)有限公司 | Method and technology for synthesizing and producing antibiotic medicament namely 1-(o-fluorophenyl) dihydropyridone |
| WO2014127919A1 (en) * | 2013-02-22 | 2014-08-28 | Karlsruher Institut für Technologie | Peptidomimetics possessing photo-controlled biological activity |
| CN106083837A (en) * | 2016-05-27 | 2016-11-09 | 浙江普洛得邦制药有限公司 | A kind of oxazolidinone antibacterial medicine and the preparation method of intermediate thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080064689A1 (en) * | 2004-05-25 | 2008-03-13 | Astrazeneca Ab | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
-
2019
- 2019-01-23 CN CN201910065066.1A patent/CN111471041B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101798302A (en) * | 2009-02-06 | 2010-08-11 | 盟科医药技术(上海)有限公司 | Method and technology for synthesizing and producing antibiotic medicament namely 1-(o-fluorophenyl) dihydropyridone |
| WO2014127919A1 (en) * | 2013-02-22 | 2014-08-28 | Karlsruher Institut für Technologie | Peptidomimetics possessing photo-controlled biological activity |
| CN106083837A (en) * | 2016-05-27 | 2016-11-09 | 浙江普洛得邦制药有限公司 | A kind of oxazolidinone antibacterial medicine and the preparation method of intermediate thereof |
Non-Patent Citations (3)
| Title |
|---|
| Improved synthesis of YG-056SP, a potent oxazolidinone antibacterial candidate against multi-drug resistant bacteria;Peng Chen et al.;《JOURNAL OF CHEMICAL RESEARCH》;20191231;第1-7页 * |
| 噁唑烷酮类抗生素药物YG-056SP关键体的合成工艺研究;陈鹏;《中国优秀博高级论文全文数据库（硕士）卫生医药科技辑》;20210715(第07期);E079-14 * |
| 噁唑烷酮类抗菌剂雷得唑来的合成;单振良 et al.;《中国药物化学杂志》;20170430;第27卷(第2期);第108-112页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111471041A (en) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3271018B1 (en) | Processes and intermediates for the preparation of pimavanserin | |
| JP6872500B2 (en) | How to make bribalacetam | |
| KR101461291B1 (en) | Process for the manufacture of pharmaceutically active compounds | |
| EP3481200B1 (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides | |
| JP2021527703A (en) | Bribalacetam intermediate, its manufacturing method and bribalacetam manufacturing method | |
| EP3668857B1 (en) | Processes for the preparation of niraparib and intermediates thereof | |
| CN102746288B (en) | Preparation methods of anticoagulant and key intermediate of anticoagulant | |
| JP2020528064A (en) | Process for preparing and purifying the LFA-1 antagonist refitegrass | |
| CN111471041B (en) | Synthetic method of oxazolidinone antibacterial drug intermediate | |
| CN115210233A (en) | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| CN109400607B (en) | Abamebactam intermediate and preparation method thereof | |
| CN108610306B (en) | Synthetic method of 2H-1, 4-thiazine-3 (4H) -ketone derivative | |
| CN112500419A (en) | Epoxy fused 2-methylene pyrrolidine compound and preparation method thereof | |
| WO2012157504A1 (en) | β-LACTAM COMPOUND AND METHOD FOR PRODUCING SAME | |
| KR101686087B1 (en) | Process for Production of Optically Active Indoline Derivatives or Salts Thereof | |
| US11932631B2 (en) | Process for preparing aficamten | |
| JP2002371060A (en) | Method for producing optically active aminopiperidine derivative | |
| JPH04270272A (en) | Production of aminoalkylmorpholine derivative | |
| CN110551170B (en) | Synthesis method of C-19 single-acyl triptolide derivative | |
| CN107325092B (en) | Novel preparation process of azithromycin | |
| JP4528884B2 (en) | Naphthalene-2-carboxylate derivative useful for the synthesis of gemcitabine and method for producing the same | |
| KR101881918B1 (en) | New process for the synthesis of acylsulfonamides derivatives | |
| CA2940609A1 (en) | Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol | |
| CN116283761A (en) | 3-alkenyl ketone substituted quinoline-2-ketone and green synthesis method thereof | |
| JP2969946B2 (en) | 3.6-Diamino-2,5-pyrazinedicarbonitrile and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |